, Tracking Stock Market Picks
Enter Symbol:

down 73.02 %

MEDIVATION INC (MDVN) downgraded to Hold with price target $45 by Canaccord Genuity

Posted on: Wednesday,  Jan 27, 2016  9:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Hold MEDIVATION INC (NASDAQ: MDVN) on 01/27/2016. Previously Canaccord Genuity rated Buy MEDIVATION INC (NASDAQ: MDVN) on 04/08/2015.,
when the stock price was $129.60. Since then, MEDIVATION INC has lost 73.02% as of 01/27/2016's recent price of $34.96.
If you would have followed the previous Canaccord Genuity's recommendation on MDVN, you would have lost 73.02% of your investment in 294 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/27/2016 9:25 AM Hold
34.96 45.00
as of 8/27/2015
1 Week down  -10.35 %
1 Month down  -20.67 %
3 Months down  -25.37 %
1 YTD down  -28.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/8/2015 9:25 AM Buy
129.60 180.00
9/18/2014 9:25 AM Buy
99.80 132.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy